Health Professional Radio - Podcast
KEYTRUDA Phase 3 KEYNOTE-522 Trial Data
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:08:44
- Mas informaciones
Informações:
Sinopsis
Dr. Jonathan Cheng with Merck Research Laboratories discusses data presented at the European Society for Medical Oncology (ESMO) 2019 Congress on the phase 3 KEYNOTE-522 trial of Merck's KEYTRUDA® plus chemotherapy in early stage triple negative breast cancer.
